Literature DB >> 22508546

Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.

Patricia Quach1, Elaine Gutierrez, Maram Talal Basha, Danuta S Kalinowski, Philip C Sharpe, David B Lovejoy, Paul V Bernhardt, Patric J Jansson, Des R Richardson.   

Abstract

Thiosemicarbazones are a group of compounds that have received comprehensive investigation as anticancer agents. The antitumor activity of the thiosemicarbazone, 3-amino-2-pyridinecarboxaldehyde thiosemicarbazone (3-AP; triapine), has been extensively assessed in more than 20 phase I and II clinical trials. These studies have demonstrated that 3-AP induces methemoglobin (metHb) formation and hypoxia in patients, limiting its usefulness. Considering this problem, we assessed the mechanism of metHb formation by 3-AP compared with that of more recently developed thiosemicarbazones, including di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT). This was investigated using intact red blood cells (RBCs), RBC lysates, purified oxyhemoglobin, and a mouse model. The chelation of cellular labile iron with the formation of a redox-active thiosemicarbazone-iron complex was found to be crucial for oxyhemoglobin oxidation. This observation was substantiated using a thiosemicarbazone that cannot ligate iron and also by using the chelator, desferrioxamine, that forms a redox-inactive iron complex. Of significance, cellular copper chelation was not important for metHb generation in contrast to its role in preventing tumor cell proliferation. Administration of Dp44mT to mice catalyzed metHb and cardiac metmyoglobin formation. However, ascorbic acid administered together with the drug in vivo significantly decreased metHb levels, providing a potential therapeutic intervention. Moreover, we demonstrated that the structure of the thiosemicarbazone is of importance in terms of metHb generation, because the DpT analog, di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), does not induce metHb generation in vivo. Hence, DpC represents a next-generation thiosemicarbazone that possesses markedly superior properties. This investigation is important for developing more effective thiosemicarbazone treatment regimens.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22508546     DOI: 10.1124/mol.112.078964

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

1.  Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcription.

Authors:  Namita Kumari; Sergey Iordanskiy; Dmytro Kovalskyy; Denitra Breuer; Xiaomei Niu; Xionghao Lin; Min Xu; Konstantin Gavrilenko; Fatah Kashanchi; Subhash Dhawan; Sergei Nekhai
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool.

Authors:  Asikiya Walcourt; Joseph Kurantsin-Mills; John Kwagyan; Babafemi B Adenuga; Danuta S Kalinowski; David B Lovejoy; Darius J R Lane; Des R Richardson
Journal:  J Inorg Biochem       Date:  2013-08-26       Impact factor: 4.155

3.  Disulfide-masked iron prochelators: Effects on cell death, proliferation, and hemoglobin production.

Authors:  E A Akam; R D Utterback; J R Marcero; H A Dailey; E Tomat
Journal:  J Inorg Biochem       Date:  2018-01-04       Impact factor: 4.155

4.  A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate--ZMC1.

Authors:  Hongxia Lin; Xin Yu; Oliver S Eng; Brian Buckley; Ah-Ng Tony Kong; Joseph R Bertino; Darren R Carpizo; Murugesan K Gounder
Journal:  Biomed Chromatogr       Date:  2015-05-05       Impact factor: 1.902

5.  Kinetic studies on the oxidation of oxyhemoglobin by biologically active iron thiosemicarbazone complexes: relevance to iron-chelator-induced methemoglobinemia.

Authors:  Maram T Basha; Carlos Rodríguez; Des R Richardson; Manuel Martínez; Paul V Bernhardt
Journal:  J Biol Inorg Chem       Date:  2013-12-08       Impact factor: 3.358

6.  Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling.

Authors:  Xiongzhi Wangpu; Jiaoyang Lu; Ruxing Xi; Fei Yue; Sumit Sahni; Kyung Chan Park; Sharleen Menezes; Michael L H Huang; Minhua Zheng; Zaklina Kovacevic; Des R Richardson
Journal:  Mol Pharmacol       Date:  2016-02-19       Impact factor: 4.436

Review 7.  Harnessing microbial iron chelators to develop innovative therapeutic agents.

Authors:  Marta Ribeiro; Cátia A Sousa; Manuel Simões
Journal:  J Adv Res       Date:  2021-11-01       Impact factor: 12.822

8.  Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping.

Authors:  Judith M Myers; Qing Cheng; William E Antholine; Balaraman Kalyanaraman; Aleksandra Filipovska; Elias S J Arnér; Charles R Myers
Journal:  Free Radic Biol Med       Date:  2013-02-26       Impact factor: 7.376

9.  The anticancer agent di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity.

Authors:  Elaine Gutierrez; Des R Richardson; Patric J Jansson
Journal:  J Biol Chem       Date:  2014-10-09       Impact factor: 5.157

10.  In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.

Authors:  Ye-Xing Xu; Man-Li Zeng; Di Yu; Jie Ren; Fen Li; Anyuan Zheng; Yong-Ping Wang; Chen Chen; Ze-Zhang Tao
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.